JAK2 and myeloproliferative neoplasm: Currently, there are no data in the literature regarding the possible association between NBTE and classical risk factors of thrombophilia, including protein C, protein S, and anti-thrombin deficiencies; factor V Leiden G1691A and factor II G20210A mutations [61]; as well as emerging candidates like the Janus kinase 2 (JAK2) V617F mutation [62], the driver mutation of polycythemia vera-like myeloproliferative neoplasms [63].